Liquidia (LQDA) Cost of Revenue (2020 - 2026)
Liquidia's (LQDA) quarterly Cost of Revenue came in at $11.1 million in Q1 2026, up 630.32% year-on-year from $1.5 million in Q1 2025, and up 115.67% quarter-over-quarter from $5.1 million in Q4 2025.
Liquidia (LQDA) Cost of Revenue (2020 - 2026) Analysis & Trends
Liquidia's Cost of Revenue history runs 7 years deep, the most recent figure standing at $11.1 million for Q1 2026.
- On a quarterly basis, Cost of Revenue rose 630.32% year-over-year to $11.1 million in Q1 2026; TTM through Mar 2026 was $19.8 million, a 234.0% increase from a year earlier, with the FY2025 full-year figure at $8.8 million, up 50.09% from the prior year.
- Cost of Revenue rose to $11.1 million in Q1 2026 per LQDA's latest filing, from $5.1 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $11.1 million in Q1 2026 and bottomed at $570000.0 in Q3 2023.
- The 5-year median for Cost of Revenue is $1.3 million (2025), against an average of $1.9 million.
- Across the five-year window, Cost of Revenue retreated 22.97% in 2023 and soared 630.32% in 2026, its largest moves.
- Year by year, Cost of Revenue stood at $694000.0 in 2022, then soared by 43.08% to $993000.0 in 2023, then jumped by 36.35% to $1.4 million in 2024, then soared by 279.39% to $5.1 million in 2025, then soared by 115.67% to $11.1 million in 2026.
- Per Business Quant, the three latest LQDA Cost of Revenue figures stand at $11.1 million (Q1 2026), $5.1 million (Q4 2025), and $2.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 2.01 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 641.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 2.59 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 133.40 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 2.36 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 13.80 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 586.00 Mn |
| 10 | Liquidia | 7.47 Bn | 7.25 Bn | 121.79 Mn | 11.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.08 Mn |
| Mar 31, 2026 | 11.08 Mn |
| Dec 31, 2025 | 5.14 Mn |
| Dec 31, 2025 | 5.14 Mn |
| Sep 30, 2025 | 2.30 Mn |
| Sep 30, 2025 | 2.30 Mn |
| Jun 30, 2025 | 1.29 Mn |
| Jun 30, 2025 | 1.29 Mn |
| Mar 31, 2025 | 1.52 Mn |
| Mar 31, 2025 | 1.52 Mn |
| Dec 31, 2024 | 1.35 Mn |
| Dec 31, 2024 | 1.35 Mn |
| Sep 30, 2024 | 1.57 Mn |
| Sep 30, 2024 | 1.57 Mn |
| Jun 30, 2024 | 1.49 Mn |
| Jun 30, 2024 | 1.49 Mn |
| Mar 31, 2024 | 1.47 Mn |
| Mar 31, 2024 | 1.47 Mn |
| Dec 31, 2023 | 993,000.00 |
| Dec 31, 2023 | 993,000.00 |